Phylloquinone.

Phylloquinone is cleared mainly by the liver and part of it is converted to menaquinone-4 in tissues, while MK-7 circulates far longer and reaches bone and vessel wall. Taken together they cover both the hepatic and the peripheral pools of the same carboxylation cofactor.

Both forms drive the same gamma-glutamyl carboxylase reaction but distribute differently, K1 to the liver and menaquinones to extrahepatic tissue. Doses of the two add into one functional vitamin K supply.

Vitamin K1 carboxylates glutamate residues on osteocalcin and matrix Gla protein, and it is those carboxylated residues that bind calcium ions. Calcium handling in bone matrix depends on that step being complete.

Vitamin D drives intestinal calcium absorption and raises osteocalcin expression, and vitamin K1 carboxylates that osteocalcin so it can bind mineral. One supplies the protein and the mineral, the other activates the protein.

High alpha-tocopherol intake lowers vitamin K status and blunts vitamin K-dependent carboxylation, an established antagonism at the level of normal clotting factor activation. This is an anti-synergy to declare, not a benefit.

Vitamin K1 supports synthesis of active clotting factors while long-chain omega-3s shift platelet aggregation the other way. The two pull normal clotting in opposite directions and should be recorded as an offsetting pair.

EPA and DHA reduce platelet aggregation, whereas phylloquinone is the cofactor that activates clotting factors II, VII, IX and X. Combining them means two settled, opposite influences on the same physiology.

Ginkgo constituents act on platelet aggregation while phylloquinone activates clotting factor synthesis. The direction of the interaction is established even where its size is not well quantified.

Garlic sulfur compounds dampen platelet aggregation, the opposite direction to vitamin K1's role in activating clotting factors. Formulas carrying both should record the offset.

Phylloquinone needs bile salts and mixed micelles to cross the enterocyte, and phospholipids improve micelle formation for fat-soluble vitamins. This is emulsification chemistry rather than a metabolic link.

Vitamin K1 uptake rises when it is taken with dietary fat because absorption is micelle-dependent. A lipid carrier in the same dose raises the fraction absorbed.

Activated charcoal adsorbs fat-soluble compounds in the intestinal lumen, so a phylloquinone dose taken at the same time is partly bound and not absorbed. Separating the two by several hours removes the competition.

Phylloquinone is fat-soluble and must be incorporated into mixed micelles with bile salts before it crosses the enterocyte membrane. Where bile delivery is reduced, uptake of the vitamin falls accordingly. Supplemental bile components are used in formulas for that reason, and the underlying dependence is textbook physiology.

Triglyceride must be hydrolysed to monoglyceride and free fatty acid before micelles can form and carry phylloquinone into the enterocyte. Lipase performs that hydrolysis. The dependency is settled digestive biochemistry, which is why the vitamin is taken with a fat-containing meal.

Phospholipids are a structural part of the mixed micelles that ferry fat-soluble vitamins across the unstirred water layer of the gut. Phosphatidylcholine is used in formulations to disperse phylloquinone into that phase. Established micelle chemistry; the size of any absorption difference in people is not something to state without a number.

Fat-soluble vitamins share micellar transport and chylomicron packaging, and high doses of retinol have been described as antagonising vitamin K-dependent clotting factor activity. The direction of the interaction is recognised in clinical nutrition references; the dose at which it matters is not something to assert without a figure. Worth flagging in a stack that carries a large vitamin A amount.

Phylloquinone enables gamma-carboxylation of osteocalcin, the vitamin K-dependent bone matrix protein, while magnesium is a structural component of the hydroxyapatite lattice and a cofactor across the enzymes of bone turnover. The two act at different points of the same tissue process. Both mechanisms are established; a combination trial for bone density measures was not located.

Phylloquinone supports the carboxylation of factors II, VII, IX and X, which raises coagulation capacity, while nattokinase acts on fibrin and raises clot breakdown. The two work in opposite directions on the same haemostatic balance. That opposition is worth flagging in any formula carrying both, particularly for anyone whose clotting is being managed clinically.

Bromelain has been described as reducing platelet aggregation and degrading fibrin, again the opposite direction from vitamin K-supported coagulation capacity. Neither cancels the other cleanly, and the net effect on haemostasis is not predictable from the pairing. Flag it rather than formulate around it.

Salicylates inhibit platelet cyclooxygenase and reduce thromboxane-driven aggregation. Phylloquinone acts on the coagulation cascade rather than on platelets, so the two touch different arms of haemostasis pushing opposite ways. Recorded so a stack carrying both is visible.

Gut bacteria including Bacteroides and Escherichia species produce long-chain menaquinones, which contribute to total vitamin K available to the body alongside dietary phylloquinone. Changing the microbial population therefore changes that contribution. Whether a given probiotic raises measured vitamin K status in people has not been established, so the row sits at Promising and describes a modulating relationship, not an additive one.

Inulin is fermented in the colon and shifts which bacterial genera dominate, and some of those genera are menaquinone producers. That gives a plausible route by which a prebiotic could alter endogenous vitamin K supply. The link runs through several steps without human status data behind it, so it is Early.

Boron is described as influencing calcium and magnesium handling and appears in bone-focused formulas alongside vitamin K forms. Phylloquinone's contribution there is the carboxylation of osteocalcin and matrix Gla protein. The pairing is formulation practice supported by separate mechanisms, not a measured combination, so it stays Early.

Alkaline phosphatase, a marker and participant in bone mineralisation, is a zinc metalloenzyme. Vitamin K-dependent carboxylation of osteocalcin is a separate step in the same tissue. Both facts are established; the additive value of combining them has not been measured, so this is recorded at Early.

Ascorbate is the cofactor for prolyl and lysyl hydroxylases that build the collagen scaffold of bone, while phylloquinone enables carboxylation of the Gla proteins that bind calcium to that scaffold. Matrix and mineral binding are sequential requirements, not competing ones. Both mechanisms are established; the combination itself has not been trialled for bone measures.